Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

89Bio Inc (ETNB)

89Bio Inc (ETNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 979,905
  • Shares Outstanding, K 98,384
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,190 K
  • EBIT $ -191 M
  • EBITDA $ -197 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.94

Options Overview Details

View History
  • Implied Volatility 64.02% ( -6.30%)
  • Historical Volatility 64.17%
  • IV Percentile 11%
  • IV Rank 31.62%
  • IV High 141.91% on 10/01/24
  • IV Low 28.02% on 08/20/24
  • Put/Call Vol Ratio 12.38
  • Today's Volume 1,405
  • Volume Avg (30-Day) 1,199
  • Put/Call OI Ratio 1.79
  • Today's Open Interest 23,826
  • Open Int (30-Day) 18,723

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.59
  • Number of Estimates 4
  • High Estimate -0.53
  • Low Estimate -0.73
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -18.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.10 +44.37%
on 10/10/24
10.53 -2.66%
on 11/08/24
+2.84 (+38.33%)
since 10/08/24
3-Month
7.00 +46.43%
on 10/03/24
10.53 -2.66%
on 11/08/24
+2.26 (+28.29%)
since 08/08/24
52-Week
6.88 +48.98%
on 11/13/23
16.63 -38.36%
on 03/04/24
+2.22 (+27.65%)
since 11/08/23

Most Recent Stories

More News
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

ETNB : 10.21 (+2.51%)
89bio to Participate in the UBS Global Healthcare Conference

ETNB : 10.21 (+2.51%)
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

ETNB : 10.21 (+2.51%)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 10.21 (+2.51%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 3.03 (+6.69%)
GLMD : 2.91 (-5.52%)
VKTX : 67.14 (-2.48%)
ETNB : 10.21 (+2.51%)
IVA : 2.80 (+4.87%)
SGMT : 5.94 (-4.04%)
TERN : 7.36 (+4.25%)
NVO : 107.65 (+0.02%)
IQV : 219.14 (+0.67%)
MDGL : 351.16 (-1.04%)
Why Shares of 89bio Plummeted on Tuesday

So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.

AKRO : 34.55 (-0.92%)
ETNB : 10.21 (+2.51%)
Why Akero Therapeutics Stock Is Crashing Today

Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).

ETNB : 10.21 (+2.51%)
AKRO : 34.55 (-0.92%)
Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data, Powell Speech

September S&P 500 futures (ESU23) are down -0.12%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.22% this morning as market participants looked ahead to the release of the Fed’s favorite...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
TSLA : 318.63 (+7.32%)
NVDA : 147.38 (-1.01%)
JD : 38.37 (-6.94%)
PDD : 117.82 (-6.40%)
KMX : 75.64 (-1.05%)
DBK.D.DX : 15.512 (-3.13%)
AML.LN : 117.600 (-2.00%)
MLTX : 51.71 (+2.05%)
ETNB : 10.21 (+2.51%)
GOOGL : 178.78 (-1.09%)
3 Biotech Buyout Targets to Watch

The trio all have late-stage therapies with blockbuster potential.

ETNB : 10.21 (+2.51%)
KRTX : 329.83 (+0.03%)
MORF : 56.99 (+0.04%)
Why Shares of 89bio Soared This Week

The company released positive results for its lead therapy.

ETNB : 10.21 (+2.51%)

Business Summary

89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis....

See More

Key Turning Points

3rd Resistance Point 11.06
2nd Resistance Point 10.74
1st Resistance Point 10.35
Last Price 10.21
1st Support Level 9.65
2nd Support Level 9.33
3rd Support Level 8.94

See More

52-Week High 16.63
Fibonacci 61.8% 12.91
Fibonacci 50% 11.76
Fibonacci 38.2% 10.60
Last Price 10.21
52-Week Low 6.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar